Lung Diseases LD11, 2017 – 2017

Search and validation of biomarkers for tuberculosis in Mexican patients with diabetes mellitus

Funding Amount

$233,000

Background

Today, the traditional test in the health sector to assume an infection by Mycobacterium tuberculosis in asymptomatic people is based on delayed hypersensitivity immune response to a complex mixture of antigens derived from the purified protein derivative (PPD) or tuberculin, whose most abundant constituents are shared by other mycobacteria, resulting in sensitivity and specificity values of around 80%. As a solution to this lack of ability to detect at least 20% of cases based on ex vivo cell response to particular antigens of M. tuberculosis, some commercial kits were generated. Despite the progress that these methods represent, their demonstrated usefulness is not entirely satisfactory when used in various populations. Thanks to this, and taking advantage of the possibility of conducting a screening for all proteins encoded in the genome of M. tuberculosis within a chip/ protein microarray, we propose the search and validation of biomarkers for tuberculosis, specifically in Mexican patients with diabetes mellitus.

Main Objectives

Develop a diagnostic method based on a panel of mycobacterial antigenic proteins, to detect asymptomatic tuberculosis in Mexican patients with diabetes mellitus, with sensitivity and specificity greater than or equal to 80%, from antigens present in the complete proteome of M. tuberculosis

Specific objectives

1. Determine the ability to detect antigenic proteins from the complete proteome of M. tuberculosis, produced in a microarray, using antibodies present in sera from healthy subjects, patients with active tuberculosis, diabetes mellitus patients with negative PPD reactivity, and patients with diabetes mellitus and positive PPD reactivity.

2. Once identified the antigenic proteins, verify the sensitivity and specificity of detection of antigenic proteins individually, to find candidate biomarkers, and validate their recognition by sera from healthy subjects, patients with active tuberculosis, diabetes mellitus patients with negative PPD reactivity, and patients with diabetes mellitus and positive PPD reactivity.

3. Validate the cross-reactivity of candidate biomarkers in study groups and cases of diabetic patients with other infectious diseases.

Principal Investigator

Mario Alberto Flores, Center for Research and Assistance in Technology and Design of the State of Jalisco

Funding organisations

  • Lung Diseases LD11
  • Mexico
  • 2017 – 2017